Advertisement

Topics

Minerva Neurosciences, Inc.: Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates

07:40 EDT 3 Aug 2017 | FinanzNachrichten

FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second ha...

Original Article: Minerva Neurosciences, Inc.: Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates

NEXT ARTICLE

More From BioPortfolio on "Minerva Neurosciences, Inc.: Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...